Assessment of Transcultural Psychotherapy in Child Major Depressive Disorder
EDPT-ADOS
2 other identifiers
interventional
80
1 country
4
Brief Summary
The symptomatic and clinical expression of psychiatric disorders in children and adolescents is strongly influenced by the cultural setting they are growing up in. These cultural variations complicate psychiatric care, especially for migrant children, for whom appropriate care must be designed. Transcultural psychotherapy is an original psychotherapeutic technique developed to meet these specific requirements in France and in different European and American countries. Its theoretical and methodological foundations rest on the works of George Devereux in ethnopsychiatry (1970). A psychotherapeutic technique intended for first-generation migrants was developed by Tobie Nathan and coll (1986). Marie-Rose Moro and colleagues (1990) have adapted this technique to second-generation migrants. Indicated as a second-line treatment after the failure of standard management, this technique is fully formalized today. It comprises group consultations for the child and the family as a one-hour session each month, directed by a principal therapist, assisted by a group of co-therapists (of diverse cultural origins and occupations) and an interpreter in the family's mother tongue. The concept of culture is used to establish the therapeutic alliance, decode the symptoms, and propose treatment. The children and adolescents receiving this treatment have varied psychopathological profiles, mostly involving depressive and/or anxiety disorders. Specifically, migrants' children are especially vulnerable to depression, their psychiatric care is generally longer and less effective than in the general population, and their rate of treatment failure higher. Transcultural psychotherapy has demonstrated its value in these situations in numerous qualitative studies, but its efficacy has not yet been assessed by a method providing a high level of evidence, such as randomized controlled trials.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P50-P75 for not_applicable major-depressive-disorder
Started Oct 2020
Longer than P75 for not_applicable major-depressive-disorder
4 active sites
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
December 16, 2019
CompletedFirst Posted
Study publicly available on registry
December 20, 2019
CompletedStudy Start
First participant enrolled
October 28, 2020
CompletedPrimary Completion
Last participant's last visit for primary outcome
April 29, 2024
CompletedStudy Completion
Last participant's last visit for all outcomes
May 1, 2025
CompletedApril 6, 2025
March 1, 2025
3.5 years
December 16, 2019
April 4, 2025
Conditions
Keywords
Outcome Measures
Primary Outcomes (1)
Severity Score on the Improved Global Impression Scale (iCGI) to assess remission
.iCGI score is a scale ranging from 1 to 7, 1 being Normal, not at all ill, and 7 - Among the most extremely ill patients. 1. \- Normal, not at all ill 2. \- Borderline mentally ill 3. \- Mildly ill 4. \- Moderately ill 5. \- Markedly ill 6. \- Severely ill 7. \- Among the most extremely ill patients Remission is defined as a mean iCGI score over the 3 experts \<4 at 28 weeks of treatment (W34).
at week 34 visit (v5)
Secondary Outcomes (6)
Severity score on the iCGI
at baseline and weeks 6, 13, 20, 27 and 34 and 52
Score on the French version of the Children's Depression Rating Scale-Revised (CDRS-R)
at baseline and weeks 6, 13, 20, 27 and 34 and 52
Score on the French version of the State-Trait Anxiety Inventory for children (STAI-C)
at baseline and weeks 6, 13, 20, 27 and 34 and 52
Score changes in Depression and anxiety Scores between Week 34 and week 52
at 34 and 52 weeks
analysis of the content of the clinical data collected during the visits
between 34 and 44 weeks
- +1 more secondary outcomes
Study Arms (2)
Transcultural psychotherapy
EXPERIMENTALIn addition to usual care, the participants in the treatment group receive transcultural psychotherapy in the inclusion centers, which consists of 5 sessions every 7 weeks (W6, W13, W20, W27, and W34). During all the research process, participants from both groups continue their usual care provided by the referent medical team outside the inclusion center.
standard care
NO INTERVENTIONusual care provided by the referent medical team
Interventions
In addition to usual care, the participants receive transcultural psychotherapy
Eligibility Criteria
You may qualify if:
- Be a child aged or an adolescent aged 6-20 years-old (this may be a declaratory age at the time of the consultation or based on a document for a residence request if no other identity documents are available)
- Be a first or second-generation migrant (born abroad or born from at least one parent who is born abroad)
- Have a psychological and/or psychiatric follow-up by a first-line care
- Have been referred for transcultural psychotherapy by their first line care to treat depression resistant to standard management.
- Present a depression according to the clinician who proposes the transcultural treatment (first line therapist), based on usual as well as cultural symptoms criteria of the below list:
- Sadness
- Diminish interest or pleasure in most of the usual activities
- Insomnia or hypersomnia
- Psychomotor agitation
- Asthenia, loss of energy
- Feeling of worthlessness or excessive guilt
- Recurrent throughs of death
- School problems (school failure, drop in grades, aggressivity with adult, school refusal…)
- Mutism, and selective mutism
- Runaways
- +11 more criteria
You may not qualify if:
- Patient or family has previously had transcultural psychotherapy
- Patient presents an acute psychiatric disorder which hinders the realization of the transcultural therapy - for example, excited delirium with great psychic disorganization, or high suicidal risk patients. These situations will be excluded during the screening time based on the first line therapist evaluation
- Patient presents an acute somatic disease which may hinder the well organization of the therapy
- Patient addressed for a legal expertise
- Child's/Adolescent's refusal
- Pregnant or breastfeeding (for women for young women of childbearing age)
- Participation in another interventional study
- Patient under guardianship or curatorship
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (4)
Service de Psychopathologie de l'enfant, de l'adolescent, CHU Avicenne
Bobigny, France
Service de psychiatrie de l'enfant et de l'adolescent, CHRU Gabriel Montpied
Clermont-Ferrand, France
Maison de Solenn, Cochin Hospital
Paris, 75000, France
Centre Médico-psychologique, Service Universitaire de Psychiatrie de l'Enfant et de l'Adolescent, Hôpital La Grave, CHU Toulouse
Toulouse, France
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Study Officials
- PRINCIPAL INVESTIGATOR
Jonathan LACHAL, PhD
Assistance Publique - Hôpitaux de Paris
Study Design
- Study Type
- interventional
- Phase
- not applicable
- Allocation
- RANDOMIZED
- Masking
- SINGLE
- Who Masked
- OUTCOMES ASSESSOR
- Purpose
- SUPPORTIVE CARE
- Intervention Model
- PARALLEL
- Sponsor Type
- OTHER
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
December 16, 2019
First Posted
December 20, 2019
Study Start
October 28, 2020
Primary Completion
April 29, 2024
Study Completion
May 1, 2025
Last Updated
April 6, 2025
Record last verified: 2025-03
Data Sharing
- IPD Sharing
- Will not share